

**AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (COMPREHENSIVE)—COCATS 4 TASK FORCE 6: TRAINING IN NUCLEAR CARDIOLOGY**

<b>Committee Member</b>	<b>Employment</b>	<b>Consultant</b>	<b>Speaker’s Bureau</b>	<b>Ownership/ Partnership/ Principal</b>	<b>Personal Research</b>	<b>Institutional/ Organizational or Other Financial Benefit</b>	<b>Expert Witness</b>
Vasken Dilsizian (Chair)	University of Maryland School of Medicine—Professor of Medicine and Radiology; Director, Division of Nuclear Medicine	<ul style="list-style-type: none"> <li>• Astellas Pharma</li> <li>• Bracco Diagnostics</li> <li>• Fluoropharma</li> <li>• Jubilant Draximage</li> <li>• Lantheus Medical Imaging*</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• GE Healthcare</li> <li>• Siemens</li> </ul>	<ul style="list-style-type: none"> <li>• GE Healthcare</li> </ul>	None
James A. Arrighi	Rhode Island Hospital, Brown University—Program Director, Program Director Cardiology Fellowship and Associate Professor of Medicine	None	None	None	None	<ul style="list-style-type: none"> <li>• ACGME RRC†</li> </ul>	None
Rose S. Cohen	Contra Costa Regional Medical Center, Department of Cardiology—Physician Advisor	None	None	None	None	<ul style="list-style-type: none"> <li>• Contra Costa Medical Center (Director, Cardiac Imaging)†</li> </ul>	None
Todd D. Miller	Mayo Clinic—Professor of Medicine	None	None	None	None	<ul style="list-style-type: none"> <li>• Astellas Pharma</li> <li>• Forest Laboratories</li> </ul>	None
Allen J. Solomon	The George Washington University, Division of Cardiology—Associate Professor of Medicine	None	<ul style="list-style-type: none"> <li>• Bristol-Myers Squibb*</li> <li>• Janssen Pharmaceuticals</li> <li>• Sanofi-aventis</li> </ul>	None	None	None	<ul style="list-style-type: none"> <li>• Plaintiff, peri-procedural MI, 2013</li> </ul>
James E. Udelson	Tufts Medical Center—Chief, Division of Cardiology	<ul style="list-style-type: none"> <li>• Lantheus Medical Imaging</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Cytori Rx</li> <li>• Medtronic</li> <li>• NHLBI</li> <li>• Otsuka</li> </ul>	<ul style="list-style-type: none"> <li>• Circulation/AHA*</li> <li>• Circulation Heart Failure†</li> <li>• HCRI</li> <li>• HFSA†</li> <li>• Pfizer/ GlaxoSmithKline</li> </ul>	None

This table represents all healthcare relationships of committee members with industry and other entities by authors, including those not deemed to be relevant, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of  $\geq 5\%$  of the voting stock or share of the business entity, or ownership of  $\geq \$10,000$  of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please

refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACCF Disclosure Policy for Writing Committees.

\*Significant relationship.

†No financial benefit.

ACGME RRC = Accreditation Council for Graduate Medical Education Residency Review Committee; AHA = American Heart Association; MI = myocardial infarction; NHLBI = National Heart, Lung and Blood Institute.